Respira Technologies
Respira Technologies is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Respira Technologies.
Respira Technologies is a company.
Key people at Respira Technologies.
Key people at Respira Technologies.
Respira Technologies, Inc., founded in 2018 and rebranded as Qnovia, Inc. in 2022, is a clinical-stage health tech and pharmaceutical company developing proprietary inhalation device technologies, primarily the RespiRx™ device, to deliver therapeutics for smoking cessation and cardiopulmonary diseases. The company targets smokers seeking to quit—the world's largest cause of preventable death—affecting over one billion people globally, with plans to expand into asthma, COPD, vaccine delivery, pain management, and infectious diseases using generic and investigational drugs.[1][2][5][7] Qnovia's lead asset, QN-01 (RespiRx Nicotine Inhaler), received FDA IND clearance in 2024, enabling U.S. clinical trials after positive first-in-human data showed superior pulmonary delivery and pharmacokinetics compared to existing nicotine replacement therapies; the company serves patients via prescription therapies and partners with healthcare firms for broader applications.[5][7] Growth momentum includes securing financing for trials, leadership hires like ex-Altria CEO Brian Quigley, and pursuit of U.K. MHRA approval.[1][5]
(Note: A separate entity, Respira Therapeutics, focuses on pulmonary arterial hypertension therapies but is distinct based on leadership, website, and product focus.[3][6])
Respira Technologies was founded in 2018 in Los Angeles by Mario Danek, a life sciences entrepreneur with experience in CPG and medical device innovation, to create cutting-edge drug delivery platforms improving patient outcomes through superior inhalation devices.[1][2][4][5] The idea emerged from addressing limitations in traditional drug delivery, particularly for nicotine and pharmaceuticals, aiming for a carcinogen-free, pod-based system as the first entrant against tobacco-related diseases.[2][7] Early traction included developing the orientation-agnostic RespiRx™ VMN (vibrating mesh nebulizer) device, positive first-in-human studies in 2023 demonstrating dose-dependent pharmacokinetics and tolerability, and rebranding to Qnovia in September 2022 under new CEO Brian Quigley (former Altria President & CEO of smokeless/innovative products with 16 years there).[1][5] Key early team members included CSO Chris Cheng (pulmonary biologist) and product director Joe Walsh.[2] Pivotal moments: FDA IND clearance for QN-01 as the first inhalable prescription smoking cessation therapy and migration to qnovia.com.[1][5][7]
Qnovia's edge lies in its RespiRx™ platform, a proprietary, portable vibrating mesh nebulizer (VMN) device that operates in any orientation, enabling effective pulmonary delivery of aerosols where traditional systems fail.[1][5][7]
Qnovia rides the inhaled therapeutics wave, targeting smoking cessation amid rising demand for non-oral, patient-friendly drug delivery amid 8 million annual tobacco deaths. Timing aligns with post-pandemic focus on respiratory health, unmet needs in NRT efficacy (most smokers relapse), and FDA push for innovative combination products via 505(b)(2) pathways.[1][5][7] Market forces favor it: Growing biotech interest in device-enabled therapies, regulatory progress (IND clearance), and expansion potential into high-burden areas like COPD (affecting 400M globally) where peripheral lung delivery improves outcomes.[1][6] It influences the ecosystem by pioneering orientation-agnostic VMNs, enabling partners to reformulate drugs for inhalation, potentially redefining standards for adherence-challenged therapies and accelerating generic inhaled options.[7]
Qnovia is poised for clinical milestones, with U.S. Phase 1 trials imminent post-IND clearance and U.K. advancement, potentially launching the first effective inhaled smoking cessation aid. Trends like AI-optimized formulations, telehealth integration for adherence tracking, and biosimilar inhalation pushes will shape it; influence may grow via partnerships licensing RespiRx for vaccines/pain, scaling from nicotine to multi-billion respiratory markets.[5][7] Success hinges on trial data and financing, but its derisked profile positions it to save lives by transforming quitting from failure-prone patches to reliable breaths—echoing its mission since Respira's 2018 inception.[1][2]
